T he recently published American Thoracic Society/European Respiratory Society statement distinguishes idiopathic pulmonary fibrosis (IPF), also known as usual interstitial pneumonia (UIP), from the other idiopathic interstitial pneumonias (IIPs) (1). Although the current classification of IIPs is different from the one developed by Liebow and Carrington (2) in the 1960s, the description of UIP has not changed, and it is still recognized as having distinctive clinical and pathological features that distinguish it from the other IIPs. IPF responds differently to systemic corticosteroid (steroid) therapy and has a different prognosis than the other IIPs, such as nonspecific interstitial pneumonitis, which previously were felt to be variants of the same condition (1,3,4). Despite therapy, most patients with IPF experience a progressive decline in pulmonary function, leading to respiratory failure and death, unless they undergo lung transplantation.
IPF must be distinguished from the other IIPs so that it can be managed appropriately (1). The diagnosis of IPF or UIP should be confirmed by surgical biopsy or by the presence of typical high resolution computed tomography findings in patients who meet the American Thoracic Society/European Respiratory Society criteria for the diagnosis of IPF (1,3). It must be emphasized that IPF, not one of the other IIPs, is the subject of this debate (1).
The attraction to intervene and treat, rather than observe, a patient with a progressive and life-threatening disease is obvious. Before the recent recognition that IPF was a fibrotic condition rather than an inflammatory condition, it was regularly treated with steroids and other immunosuppressive medications, unlike the other IIPs that it had previously been confused with (5-7). The results of steroid treatment in patients with IPF have been reported since the 1950s (8) . Unfortunately, none of these were prospective, randomized, controlled trials, and most of the studies did not distinguish IPF from the other IIPs (7) . Approximately 25% of the patients in these trials responded to steroid treatment (7) . Some of this apparent improvement with steroid therapy was due to misdiagnosis of patients with steroid responsive IIPs and their inclusion in these studies. In controlled trials, the addition of cytotoxics, either azathioprine or cyclophosphamide, to steroids did not improve the outcome in IPF patients (7) .
Several recent studies indicate that the prognosis of patients with IPF is related to the rate of pulmonary function decline and pathological features of fibrosis, such as fibrogenic foci, rather than to therapy (5, (9) (10) (11) (12) (13) . Dismal results were reported in the studies of steroid therapy that were limited to patients with IPF and excluded patients with steroid-responsive IIPs (7). Less than 10% of the patients with IPF responded to therapy with steroids (7). These results are discouraging compared with a longitudinal study that demonstrated that 15% of patients with IPF were stable after two years without any therapy (14) . Because none of the treatment trials were placebo controlled, it is likely that the apparent improvement with treatment was due to the variability in the rate of functional decline known to occur in these patients (7, 8) . Patients are more likely to be started on treatment during a period of more rapid functional decline. The subsequent period of relative stability and even slight improvement due to the natural course of the illness may be attributed to therapy. This effect has been casually referred to as 'regression to the mean' (15) . This suggests that treatment with steroids, with or without cytotoxic therapy, is no better than supportive therapy. A review of nearly 500 patients with IPF seen at the Mayo Clinic found that survival was no better in patients treated with prednisone than in those receiving best supportive care (16) . Early treatment of IPF with steroids and cytotoxic medications exposes patients to the serious side effects of these medications without any therapeutic benefits at a time when they would otherwise still have a reasonable quality of life.
Virtually all patients treated chronically with high dose steroids experience important side effects (17) . Some of these cause significant morbidity, such as glucose intolerance, hypertension, avascular necrosis, impaired wound healing, myopathy, osteoporosis, cataracts, glaucoma, mood changes and psychosis, and require additional therapy. Some, such as adrenal suppression, gastrointestinal bleeding, and immunosuppression and opportunistic infections, may be life threatening. Cytotoxic medications also cause potentially fatal adverse effects, including bone marrow suppression, immunosuppression and opportunistic infections, and renal and liver toxicity; they also increase the risk of a variety of malignancies, including lymphoma and bladder cancer. Moreover, patients on steroids and/or cytotoxic medications require other medications to treat their potential adverse effects and they, in turn, also cause adverse effects. Cotrimoxasole, given to prevent Pneumocystis pneumonii pneumonia, may cause skin rashes and bone marrow suppression; antituberculous medications may cause liver toxicity; rifampin interferes with the metabolism of many other medications, including steroids; and biphosphonates, given to prevent steroid induced osteoporosis, may cause dyspepsia and gastroesophageal reflux.
The only proven successful treatment for IPF is lung transplantation, and the adverse effects of chronic steroid and cytotoxic therapy, including weight gain, impaired wound healing and osteoporosis, may preclude successful transplantation (18) (19) (20) .
Some have argued that IPF should be treated early, before extensive fibrosis develops. There are no data to support this recommendation, and there is no evidence that early treatment prolongs life. This unproven approach would subject patients to the various morbidities associated with steroid and cytotoxic therapy, would disrupt their lives and would impair their quality of life before their lives were disrupted by the illness itself. Moreover, adverse effects from early treatment, such as opportunistic infection, would kill some patients before they experienced significant impairment from IPF.
The leading international IPF investigators have moved beyond recommending steroids and cytotoxic therapy for the treatment of their patients (21-23): "The committee concludes that no data exist that adequately document any of the current treatment approaches improve survival or quality of life for patients with IPF" (1). A number of editorials in the leading peer reviewed journals have acknowledged that steroid and cytotoxic therapy is ineffective, and that new therapies are necessary (24, 25) . They emphasized that IPF is a fibrotic rather than an inflammatory disease, and that antifibrotic therapy is necessary to treat this condition. Recently, there have been reports from preliminary trials of a variety of antifibrotic medications for the treatment of IPF, including colchicine, pirfenidone and interferon-gamma (20) (21) (22) .
A recent editorial stated that it is necessary to acknowledge that current therapy is ineffective to encourage the search for new therapies (25) . It goes on to suggest that growth factors, regulators of apoptosis, chemokines and cytokines have been implicated in the progression of IPF and may need to be targeted in its therapy. The imbalance between the mediators of extracellular matrix deposition, such as transforming growth factor-beta-1, and mediators of extracellular matrix proteolysis, including the matrix metalloproteinases, may play a role in the pathogenesis of pulmonary fibrosis and may need to be targeted to successfully treat IPF (25) .
In conclusion, corticosteroids and cytotoxic medications are toxic drugs that cause serious, sometimes life-threatening adverse effects, and are not effective in the treatment of IPF.
Patients taking these medications require extra monitoring and testing for adverse effects. There is no evidence that they improve survival or quality of life. If patients begin taking these medications early in the course of their disease, their lives may be disrupted while they are relatively well and they may experience manifold, important adverse effects earlier in the course of their illness. Moreover, early and longer use of these medications reduces the likelihood that patients will experience a good quality of life after lung transplantation. They should not be used in the management of patients with IPF early or at any time.
